FDA Order Clears Path for Oral Fluid Drug Testing in Federal Programs

The Food and Drug Administration published a final order on Tuesday exempting certain clinical toxicology test systems from premarket notification, removing what the drug-testing industry describes as the single largest regulatory obstacle to using oral fluid — saliva — as a specimen in federal workplace drug testing programs.

The rule, "Medical Devices; Exemptions From Premarket Notification: Class II Devices; Certain Clinical Toxicology Test Systems," appears at 91 FR 63478 and took effect October 6, the day it was published. It covers 14 categories of test systems, including assays for amphetamines, cocaine, cannabinoids and opiates, with fentanyl among them, according to the National Drug and Alcohol Screening Association, the trade group that campaigned for the change.

What the order does — and does not do

The exemption releases the affected devices from the FDA's 510(k) premarket notification requirement, under which manufacturers must show a new device is substantially equivalent to an already-marketed one before selling it. Removing that step is meant to let laboratories and manufacturers invest in oral fluid testing platforms built specifically for federally regulated testing programs.

It does not change the rules of federal drug testing themselves. Test systems remain subject to FDA quality, labeling and reporting requirements, and to the mandatory guidelines that the Substance Abuse and Mental Health Services Administration sets for federal programs. Oral fluid testing cannot become a standard specimen type for those programs until HHS and the Department of Transportation finish implementing their own procedures — work the association says it will now press.

Why oral fluid testing had stalled

A urine specimen has been the default for federally regulated workplace testing for decades. Oral fluid offers advantages that laboratories and employers have argued for years: collection is directly observed, which sharply reduces the substitution and adulteration that plague urine collection, and the window of detection is shorter and closer to the time of recent use.

The science was not the bottleneck. Under the FDA's device framework, a test system intended for use in federal drug testing programs sat in a regulatory category that required premarket notification, even though the same underlying assay technology was widely used elsewhere. That carve-out is what the industry described as the barrier.

The campaign behind the change

The exemption is the product of a coalition organized by the screening association, which included its chairman, Scott Taillie; executive director Jo McGuire; chairman emeritus James Greer; drug testing expert R. H. Barry Sample; and government affairs strategist Tim Monahan. The group took its argument to HHS leadership and to Congress, resulting in an April letter to the HHS secretary signed by six members of the House, the association said.

The FDA proposed the exemption on May 1 and finalized it without modification after a public comment period that drew roughly 70 responses, most of them supportive.

"This marks the day that oral fluid testing can proceed to market," Taillie said. "For years the science was proven and the industry was ready, but a regulatory carve out stood in the way."

McGuire framed the change as a workforce safety issue: "Employers and the traveling public will be safer because of it."

Where fentanyl fits

Fentanyl's inclusion in the exempted categories lands in the middle of a broader federal effort to keep testing panels current with a supply that has changed faster than the regulations governing it. Safety-sensitive industries, from trucking to aviation to rail, operate under testing rules written before synthetic opioids reshaped the illicit market, and employers have argued that specimen types collected years ago cannot reliably capture what workers are actually exposed to now.

Public health specialists who work on overdose response treat expanded detection with a mixture of interest and caution. Better testing can identify people who need treatment, and workplace testing is often the moment when someone with an unrecognized opioid use disorder is first offered a referral. It can also push people out of jobs and into untreated use if an employer's response stops at termination — which is why federal guidance issued in September urged employers to pair overdose response with naloxone on site and clear routes to care.

The association said its next priority is speed of implementation: working with SAMHSA and the Department of Transportation so the regulatory groundwork catches up with a device pathway that is now clear.